Integrated Filing — IndAS



General information about company

Scrip Code 532872
NSE Symbol SPARC
MSEI Symbol NA
ISIN INE232I01014
Name of company Sun Pharma Advanced Research Company Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2026
Date of end of financial year 31-03-2027
Date of board meeting when results were approved 10-08-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 03-08-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter First quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended
Segment Reporting Single segment
Description of single segment Pharmaceutical Research and Development
Start date and time of board meeting 10-08-2026   11:00:00
End date and time of board meeting 10-08-2026   13:10:00
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026 01-04-2026
B Date of end of reporting period 30-06-2026 30-06-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
1 Income
Revenue from operations 3,992.00 3,992.00
Other income 2,366.00 2,366.00
Total income 6,358.00 6,358.00
2 Expenses
(a) Cost of materials consumed 766.00 766.00
(b) Purchases of stock-in-trade 0.00 0.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 0.00 0.00
(d) Employee benefit expense 2,961.00 2,961.00
(e) Finance costs 813.00 813.00
(f) Depreciation, depletion and amortisation expense 220.00 220.00
(f) Other Expenses
1 Clinical trial expenses / products development expense 1,326.00 1,326.00
2 Professional charges 1,519.00 1,519.00
3 Other expenses 820.00 820.00
Total other expenses 3,665.00 3,665.00
Total expenses 8,425.00 8,425.00
3 Total profit before exceptional items and tax (2,067.00) (2,067.00)
4 Exceptional items 0.00 0.00
5 Total profit before tax (2,067.00) (2,067.00)
6 Tax expense
7 Current tax 2.00 2.00
8 Deferred tax 9.00 9.00
9 Total tax expenses 11.00 11.00
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations (2,078.00) (2,078.00)
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period (2,078.00) (2,078.00)
17 Other comprehensive income net of taxes 0.00 0.00
18 Total Comprehensive Income for the period (2,078.00) (2,078.00)
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent (2,076.00) (2,076.00)
Total profit or loss, attributable to non-controlling interests 0.00 0.00
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent 0.00 0.00
Total comprehensive income for the period attributable to owners of parent non-controlling interests 0.00 0.00
21 Details of equity share capital
Paid-up equity share capital 3,245.00 3,245.00
Face value of equity share capital 1 1
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations -0.64 -0.64
Diluted earnings (loss) per share from continuing operations -0.64 -0.64
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations -0.64 -0.64
Diluted earnings (loss) per share from continuing and discontinued operations -0.64 -0.64
24 Debt equity ratio 0 0
25 Debt service coverage ratio 0 0
26 Interest service coverage ratio 0 0
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) 1 These unaudited consolidated financial results relate to Sun Pharma Advanced Research Company Limited (the 'Company') and its Wholly Owned Subsidiaries (together the ‘Group’) and are prepared by applying Ind AS 110 - Consolidated Financial Statements. 2 The above unaudited consolidated financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 10, 2026. 3 The above unaudited consolidated financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder. 4 The Government of India had consolidated 29 existing labour legislations into a unified framework comprising four labour codes as follows: Code on Wages, 2019, Code on Social Security, 2020, Industrial Relations Code, 2020 and Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the New Labour Codes). The New Labour Codes were effective from November 21, 2025 and introduced changes that included, among other things, setting a uniform definition of wages. The New Labour Codes had implications on employee benefits including gratuity, leave encashment, and other related obligations. The Group had assessed the implications of the New Labour Codes and had recognized an incremental cost of Rs.1,236 lakhs during the previous year and disclosed it as an exceptional item. 5 During the quarter ended June 30, 2026, the Group and CMS Bridging DMCC (CMS) mutually agreed to terminate the licensing agreement dated November 5, 2019. Pursuant to this termination, the Group refunded USD 2 million (Rs.1,889 lakhs) to CMS and recognised revenue of Rs.2,921 lakhs relating to the non-refundable consideration. 6 During the quarter ended March 31, 2026, the Group recognised income of Rs.184,002 lakhs in respect of a Priority Review Voucher (PRV) granted by the United States Food and Drug Administration (USFDA) on February 03, 2026 for Sezaby�. The PRV, being a transferable instrument, was sold by the Group on April 30, 2026 for USD 195 million. The PRV was accounted as a non-monetary government grant under Ind AS 20 and the fair value of the PRV was recognised in the Statement of Profit and Loss. 7 On May 19, 2026, the Parent Company has allotted 3,85,10,000 warrants, each convertible into one equity share, on preferential basis to Shanghvi Finance Private Limited at an issue price of Rs.155.80/- each, upon receipt of 25% of the issue price (i.e. Rs.38.95 per warrant) as warrant subscription money. Balance 75% of the issue price (i.e. Rs.116.85 per warrant) shall be payable within 18 months from the allotment date, at the time of exercising the option to apply for fully paid–up equity share of Rs.1/- each of the Parent Company, against each warrant held by the warrant holder. 8 The Group has only one reportable business segment namely 'Pharmaceutical Research and Development'. 9 The figures for the quarter ended March 31, 2026 represent the derived figures between the audited figures in respect of the full financial year ended March 31, 2026 and the unaudited published year-to-date figures upto December 31, 2025, being the date of the end of third quarter of the financial year, which were subjected to a limited review by the statutory auditor of the Group.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2026 01-04-2026
Date of end of reporting period 30-06-2026 30-06-2026
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026 01-04-2026
B Date of end of reporting period 30-06-2026 30-06-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
Total Amount of items that will not be reclassified to profit and loss
2 Income tax relating to items that will not be reclassified to profit or loss 0.00 0.00
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income 0.00 0.00





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Unaudited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 SRBC AND CO LLP Yes 28-02-2029